🏅 FDA Orphan Designation
Tiglutik
riluzole oral suspension
Manufacturer: Italfarmaco SpA
Indicated for:
FDA-Approved Indications (1)
Amyotrophic Lateral Sclerosis (ALS)Orphan Designation
TIGLUTIK is indicated for the treatment of amyotrophic lateral sclerosis (ALS).
Indications & Usage
1 INDICATIONS AND USAGE TIGLUTIK is indicated for the treatment of amyotrophic lateral sclerosis (ALS). TIGLUTIK is indicated for the treatment of amyotrophic lateral sclerosis (ALS) ( 1 )
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.